name	nt_name	aa_name	multi_aa_name	multiaa_comb_mutation	start	vcf_gene	chrom_region	mutation_type	sequence_depth	sample_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao	reference_seq	variant_seq	viral_lineages	function_category	citation	comb_mutation	function_description	heterozygosity	clade_defining	who_variant	status	voi_designation_date	voc_designation_date	vum_designation_date
c.-3delA	c.-3delA				28270	N	intergenic		93	96						0	93	TA	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
c.C-25T	c.C-25T				241	orf1ab	5' UTR		96	96						0	96	C	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.3676del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'S3675del', 'F3677del'	11287	orf1ab	ORF1ab		192	96			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	192	GTCTGGTTTT	G	B.1.619, B.1.619					False	True, True	Unnamed	VUM			14-Jul-2021
p.A2123V	c.C6368T	p.A2123V			6633	orf1ab	ORF1ab	MISSENSE	96	96			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	96	C	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.A475A	c.C1425T	p.A475A			22987	S	S	SILENT	96	96						0	96	C	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	ACE2 receptor binding affinity	Gong et al. (2021)	'E484K'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	ACE2 receptor binding affinity	Gong et al. (2021)	'T1027I'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G.	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	ACE2 receptor binding affinity	Li et al. (2020)		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	convalescent plasma binding	Gong et al. (2021)	'E484K'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	convalescent plasma binding	Gong et al. (2021)	'T1027I'	1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	convalescent plasma escape	Tada et al. (2021)	'E484K'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	immunosuppression variant emergence	Landis et al. (2021)		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	reinfection	Rani et al. (2021)	'N440K'	A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	syncytium formation	Kim et al. (2021)		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	tissue specific neutralization	Planas et al. (2021)		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	trafficking	Barrett et al. (2021)		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	trafficking	Daniloski et al. (2021)		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	trafficking	Kim et al. (2021)		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	trafficking	Kim et al. (2021)		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	trafficking	Kuzmina et al. (2021)	'E484K'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	trafficking	Ozono et al. (2020)		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	trafficking	Zhang et l. (2020)		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	vaccine neutralization efficacy	Kuzmina et al. (2021)		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	vaccine neutralization efficacy	Kuzmina et al. (2021)	'E484K'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	vaccine neutralization efficacy	Tada et al. (2021)	'E484K'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	vaccinee plasma binding	Gong et al. (2021)	'E484K'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	vaccinee plasma binding	Gong et al. (2021)	'T1027I'	1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	viral load	Plante et al. (2020)		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	virion structure	Spratt et al. (2021)		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	virion structure	Weissman et al. (2020)		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	virion structure	Yurkovetskiy et al. (2020)		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	True	Unnamed	VUM			14-Jul-2021
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	96	96						0	96	A	G	B.1.619	virion structure	Zhang et al. (2020)		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	True	Unnamed	VUM			14-Jul-2021
p.D936N	c.G2806A	p.D936N			24368	S	S	MISSENSE	96	96						0	96	G	A	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.E22D	c.G66T	p.E22D			27459	ORF7a	ORF7a	MISSENSE	96	96						0	96	G	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.E2607K	c.G7819A	p.E2607K			8084	orf1ab	ORF1ab	MISSENSE	92	96			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	92	G	A	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	ACE2 receptor binding affinity	Collier et al. (2021)		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	ACE2 receptor binding affinity	Laffeber et al. (2021)		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	ACE2 receptor binding affinity	Liu et al. (2021)		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	ACE2 receptor binding affinity	Ramanathan et al. (2021)		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	ACE2 receptor binding affinity	Starr et al. (2020)		Experimentally, ACE2 binding affinity increased 0.06 fold	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	ACE2 receptor binding affinity	Tian et al. (2021)		Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	ACE2 receptor binding affinity	Tian et al. (2021)		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	ACE2 receptor binding affinity	Vogel et al. (2021)		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	ACE2 receptor binding affinity	Zahradnik et al. (2021)		Among the first selected variants in an in vitro evolution experiment for ACE2 binding.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	T cell evasion	Reynolds et al. (2021)		Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	antibody epitope effects	Chen et al. (2021)		Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	antibody epitope effects	Collier et al. (2021)		Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	antibody epitope effects	Gaebler et al. (2021)		Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	antibody epitope effects	Li et al. (2021)		Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	antibody epitope effects	Liu et al. (2020)		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	antibody epitope effects	Rappazzo et al. (2021)		Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	antibody epitope effects	Sun et al. (2021)		Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	antibody epitope effects	Wang et al. (2021)		Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus)	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	antibody epitope effects	Wang et al. (2021)		Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	convalescent plasma binding	Gong et al. (2021)	'D614G'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	convalescent plasma escape	Alenquer et al. (2021)		Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	convalescent plasma escape	Andreano et al. (2020)		This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	convalescent plasma escape	Cele et al. (2021)		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	convalescent plasma escape	Liu et al. (2021)		Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	convalescent plasma escape	Schmidt et al. (2021)		Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	convalescent plasma escape	Tada et al. (2021)		The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees)	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	convalescent plasma escape	Tada et al. (2021)	'D614G'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	convalescent plasma escape	Tang et al. (2021)		As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	convalescent plasma escape	Wang et al. (2021)		The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	convalescent plasma escape	Wibmer et al. (2021)		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	convalescent plasma escape	Wibmer et al. (2021)		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	convalescent plasma escape	Zhou et al. (2021)		"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	monoclonal antibody serial passage escape	Barnes et al. (2020)		The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	monoclonal antibody serial passage escape	Baum et al. (2020)		Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	monoclonal antibody serial passage escape	Greaney et al. (2020)		Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	monoclonal antibody serial passage escape	Starr et al. (2021)		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	monoclonal antibody serial passage escape	Wang et al. (2021)		Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	monoclonal antibody serial passage escape	Weisblum et al. (2020)		Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	pharmaceutical effectiveness	Engelhart et al. (2021)		Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	pharmaceutical effectiveness	Engelhart et al. (2021)		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	pharmaceutical effectiveness	Liu et al. (2021)		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	trafficking	Ferriera et al (2021)		This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. 	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	trafficking	Kuzmina et al. (2021)	'D614G'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	trafficking	Tada et al. (2021)		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	vaccine neutralization efficacy	Ferreira et al. (2021)		Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	vaccine neutralization efficacy	Ikegame et al. (2021)		E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	vaccine neutralization efficacy	Jangra et al. (2021)		Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain. 	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	vaccine neutralization efficacy	Kuzmina et al. (2021)	'D614G'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	vaccine neutralization efficacy	Solfrosi et al. (2021)		Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test). 	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	vaccine neutralization efficacy	Tada et al. (2021)	'D614G'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	vaccine neutralization efficacy	Wang et al. (2021)		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	vaccinee plasma binding	Gong et al. (2021)	'D614G'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Unnamed	VUM			14-Jul-2021
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	96	96						0	96	G	A	B.1.619	virion structure	Spratt et al. (2021)		Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type) 	False	True	Unnamed	VUM			14-Jul-2021
p.E6712E	c.A20136G	p.E6712E			20400	orf1ab	ORF1ab	SILENT	96	96			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	0	96	A	G	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.F28F	c.C84T	p.F28F			26606	M	M	SILENT	96	96						0	96	C	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.F3018F	c.C9054T	p.F3018F			9319	orf1ab	ORF1ab	SILENT	96	96			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	0	96	C	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.F3677del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'S3675del', '3676del'	11287	orf1ab	ORF1ab		96	96			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	96	GTCTGGTTTT	G	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.F4713F	c.C14139T	p.F4713F			14403	orf1ab	ORF1ab	SILENT	96	96			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	96	C	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.F924F	c.C2772T	p.F924F			3037	orf1ab	ORF1ab	SILENT	96	96			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	96	C	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.G26S	c.G76A	p.G26S			27469	ORF7a	ORF7a	MISSENSE	96	96						0	96	G	A	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.G4178V	c.G12533T	p.G4178V			12798	orf1ab	ORF1ab	MISSENSE	96	96			nsp9	ssRNA-binding protein, produced by both pp1a and pp1ab	YP_009725305.1	75	21	G	T	B.1.619					False	False	Unnamed	VUM			14-Jul-2021
p.I210T	c.T629C	p.I210T			22191	S	S	MISSENSE	96	96						0	96	T	C	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.I82T	c.T245C	p.I82T			26767	M	M	MISSENSE	96	96						0	96	T	C	B.1.619	homoplasy	Shen et al. (2021)		This mutation presents mainly within the B.1 (44.0%) and B.1.525 (38.1%) lineages.  Currently, 99.7% of the B.1.525 lineage isolates carry the M:I82T mutation. While this mutation is scattered across multiple  phylogenetic clades, most cases cluster in two recent clades, suggesting a likely selective advantage in certain haplotype backgrounds.	False	True	Unnamed	VUM			14-Jul-2021
p.K714K	c.G2142A	p.K714K			2407	orf1ab	ORF1ab	SILENT	96	96			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	96	G	A	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.L4070L	c.C12208T	p.L4070L			12473	orf1ab	ORF1ab	SILENT	96	96			nsp8	produced by both pp1a and pp1ab	YP_009725304.1	0	96	C	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.L56L	c.C168T	p.L56L			28441	N	N	SILENT	96	96						0	96	C	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.L878L	c.T2632C	p.L878L			24194	S	S	SILENT	96	96						0	96	T	C	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.M3752I	c.G11256T	p.M3752I			11521	orf1ab	ORF1ab	MISSENSE	192	96			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	192	G	T	B.1.619, B.1.619					False	True, True	Unnamed	VUM			14-Jul-2021
p.N2682N	c.C8046T	p.N2682N			8311	orf1ab	ORF1ab	SILENT	96	96			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	96	C	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	96	96						0	96	T	G	B.1.619	ACE2 receptor binding affinity	Starr et al. (2020)		Experimentally, ACE2 binding affinity increased 0.07 fold	False	True	Unnamed	VUM			14-Jul-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	96	96						0	96	T	G	B.1.619	antibody epitope effects	Cheng et al. (2021)		N501Y substitution decreased the neutralizing and binding activities of CB6 and increased that of BD-23	False	True	Unnamed	VUM			14-Jul-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	96	96						0	96	T	G	B.1.619	antibody epitope effects	Gaebler et al. (2021)		Ablates binding by class 3 mAbs such as C135 that do not directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	True	Unnamed	VUM			14-Jul-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	96	96						0	96	T	G	B.1.619	antibody epitope effects	Rappazzo et al. (2021)		Greater than 10-fold reduction of binding effeiency vs wild type for mAb LY-CoV555. Abolishes binding of mAb ADG-1.	False	True	Unnamed	VUM			14-Jul-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	96	96						0	96	T	G	B.1.619	antibody epitope effects	Wang et al. (2021)		Resistent to class 3 antibodies (i.e. Abs that do not directly interfere with ACE2 binding).	False	True	Unnamed	VUM			14-Jul-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	96	96						0	96	T	G	B.1.619	monoclonal antibody serial passage escape	Wang et al. (2021)		Class 3 antibody C669 mildly selected for the emergence of the N440K mutation in vitro (in contrast to N440H which caused mild escape in Class 1/2 mAb C653).	False	True	Unnamed	VUM			14-Jul-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	96	96						0	96	T	G	B.1.619	monoclonal antibody serial passage escape	Weisblum et al. (2020)		Positive selection (up to 45% of supernatant sequences) under two rounds of C135 monoclonal antibody passage, eliminated in subsequent passages	False	True	Unnamed	VUM			14-Jul-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	96	96						0	96	T	G	B.1.619	reinfection	Rani et al. (2021)	'D614G'	A 47yo Indian male was reinfected with B.1.36 lineage virus in September 2020 after infection with genetically distinct B.1.36 virus in  July, with negative PCR tests in between. While the forst episode was asymptomatic, the second included fever, cough, and malaise.  The second case additionally contained stopgain ORF3a:E261*	False	True	Unnamed	VUM			14-Jul-2021
p.N440K	c.T1320G	p.N440K			22882	S	S	MISSENSE	96	96						0	96	T	G	B.1.619	transmissibility	Tandel et al. (2021)		The N440K variant produced ten times higher infectious viral titers than a prevalent A2a strain,  and over 1000 folds higher titers than a much less prevalent A3i strain prototype in Caco2 cells.  Interestingly, A3i strain showed the highest viral RNA levels, but the lowest infectious titers  in the culture supernatants, indicating the absence of correlation between the RNA content and the infectivity of the sample.	False	True	Unnamed	VUM			14-Jul-2021
p.N5020N	c.C15060T	p.N5020N			15324	orf1ab	ORF1ab	SILENT	96	96			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	96	C	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.P132P	c.G396T	p.P132P			26918	M	M	SILENT	96	96						0	96	G	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.P13L	c.C38T	p.P13L			28311	N	N	MISSENSE	96	96						0	96	C	T	B.1.619	T cell evasion	de Silva et al. (2021)		Variant causes complete loss of T cell line responsiveness to B*27:05-restricted CD8+ N epitope QRNAPRITF 1-17(2,13).	False	True	Unnamed	VUM			14-Jul-2021
p.P13L	c.C38T	p.P13L			28311	N	N	MISSENSE	96	96						0	96	C	T	B.1.619	homoplasy	Borges et al. (2021)		In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation appears convergent. 	False	True	Unnamed	VUM			14-Jul-2021
p.P25P	c.C75T	p.P25P			21637	S	S	SILENT	96	96						0	96	C	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.P4715L	c.C14144T	p.P4715L			14408	orf1ab	ORF1ab	MISSENSE	96	96			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	96	C	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.P56H	c.C167A	p.P56H			28060	ORF8	ORF8	MISSENSE	96	96						55	41	C	A	B.1.619					False	False	Unnamed	VUM			14-Jul-2021
p.S201I	c.G602T	p.S201I			28875	N	N	MISSENSE	96	96						0	96	G	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.S2488F	c.C7463T	p.S2488F			7728	orf1ab	ORF1ab	MISSENSE	96	96			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	96	C	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.S3675del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'3676del', 'F3677del'	11287	orf1ab	ORF1ab		96	96			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	96	GTCTGGTTTT	G	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.S939F	c.C2816T	p.S939F			24378	S	S	MISSENSE	96	96						0	96	C	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	96	96						0	96	C	T	B.1.619	ACE2 receptor binding affinity	Gong et al. (2021)	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.69x decrease in binding (KD) relative to D614G.	False	True	Unnamed	VUM			14-Jul-2021
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	96	96						0	96	C	T	B.1.619	convalescent plasma binding	Gong et al. (2021)	'D614G'	1.56x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	True	Unnamed	VUM			14-Jul-2021
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	96	96						0	96	C	T	B.1.619	vaccinee plasma binding	Gong et al. (2021)	'D614G'	1.32x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.22x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	True	Unnamed	VUM			14-Jul-2021
p.T1027I	c.C3080T	p.T1027I			24642	S	S	MISSENSE	96	96						0	96	C	T	B.1.619	virion structure	Spratt et al. (2021)		Estimated free energy change (ddG) for this variant is 1.51 kcal/mol (i.e. stabilizing relative to wild type) 	False	True	Unnamed	VUM			14-Jul-2021
p.T1581T	c.G4743T	p.T1581T			5008	orf1ab	ORF1ab	SILENT	96	96			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	96	G	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.T205I	c.C614T	p.T205I			28887	N	N	MISSENSE	96	96						0	96	C	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.T5805M	c.C17414T	p.T5805M			17678	orf1ab	ORF1ab	MISSENSE	96	96			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	96	C	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.T6566T	c.G19698A	p.T6566T			19962	orf1ab	ORF1ab	SILENT	96	96			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	0	96	G	A	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
p.V273V	c.G819T	p.V273V			26211	ORF3a	ORF3a	SILENT	96	96						0	96	G	T	B.1.619					False	True	Unnamed	VUM			14-Jul-2021
